Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer

被引：29
|
作者：
Merseburger, Axel S. [1 ]
Bellmunt, Joaquim [2 ]
Jenkins, Cheryl [3 ]
Parker, Chris [4 ]
Fitzpatrick, John M. [5 ,6 ]
机构：
[1] Hannover Med Sch, Dept Urol & Urol Oncol, D-30625 Hannover, Germany
[2] Univ Hosp Mar, Inst Invest Med, Med Oncol Serv, Barcelona, Spain
[3] Rocket Sci Med Commun, Wantage, Oxon, England
[4] Royal Marsden Natl Hlth Serv Fdn Trust, Sutton, Surrey, England
[5] Mater Misericordiae Hosp Univ Coll, Dept Surg, Dublin, Ireland
[6] Irish Canc Soc, Dublin, Ireland
来源：
ONCOLOGIST | 2013年 / 18卷 / 05期
关键词：
Metastatic castration-resistant; Prostate cancer; Treatment; Docetaxel; Cabazitaxel; Abiraterone acetate; Enzalutamide; CIRCULATING TUMOR-CELLS; ANDROGEN RECEPTOR GENE; MITOXANTRONE PLUS PREDNISONE; PHASE-II TRIAL; CLINICAL-TRIALS; BONE METASTASES; SIPULEUCEL-T; SKELETAL COMPLICATIONS; ABIRATERONE ACETATE; INCREASED SURVIVAL;
D O I：
10.1634/theoncologist.2012-0478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The arrival of several new agents-cabazitaxel, abiraterone acetate, enzalutamide, and radium-223-is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.
引用
收藏
页码：558 / 567
页数：10
相关论文
共 50 条
  • [21] Management of Metastatic Castration-Resistant Prostate Cancer
    Srinivas, Sandy
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 614 - 616
  • [22] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    Heidegger, Isabel
    Pircher, Andreas
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 890 - 891
  • [23] Cabazitaxel in metastatic castration-resistant prostate cancer
    Yap, Timothy A.
    Pezaro, Carmel J.
    de Bono, Johann S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1129 - 1136
  • [24] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer (vol 18, pg 558, 2013)
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (08): : 971 - 971
  • [25] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer (vol 18, pg 558, 2013)
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (06): : 775 - 775
  • [26] Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives
    Akkus, Erman
    Arslan, Cagatay
    Urun, Yuksel
    CANCER TREATMENT REVIEWS, 2024, 130
  • [27] Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives
    Ruiz de Porras, Vicenc
    Font, Albert
    Aytes, Alvaro
    CANCER LETTERS, 2021, 523 : 162 - 169
  • [28] Apalutamide for the Treatment of non-metastatic castration-resistant Prostate Cancer
    Miller, Kurt
    ONKOLOGE, 2019, 25 (03): : 275 - 276
  • [29] Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2013, 9 (05) : 619 - 622
  • [30] Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer
    Armstrong, Andrew J.
    Eisenberger, Mario A.
    Halabi, Susan
    Oudard, Stephane
    Nanus, David M.
    Petrylak, Daniel P.
    Sartor, A. Oliver
    Scher, Howard I.
    EUROPEAN UROLOGY, 2012, 61 (03) : 549 - 559
12345